TRACON Pharmaceuticals, Inc. Stock

TCON

US89237H3084

Pharmaceuticals

Market Closed - OTC Markets 15:02:49 2024-12-02 EST			5-day change	1st Jan Change
0.0322 ^USD	-26.01%		-.--%	-

24-10-10	TRACON Pharmaceuticals, Inc. announced a financing transaction	CI
24-08-13	TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI

Valuation: TRACON Pharmaceuticals, Inc.

Market Cap	110K 95.68K 90.34K 82.04K 154K 10.53M 154K 1.08M 418K 5.35M 412K 403K 17.22M	P/E 2022	-1.07x	P/E 2023	-1.59x
Enterprise Value	-7.49M -6.53M -6.16M -5.6M -10.49M -718M -10.53M -73.84M -28.49M -365M -28.12M -27.5M -1.18B	EV / Sales 2022	-	EV / Sales 2023	-0.18x
Free-Float	98.27%	Yield 2022 *	-	Yield 2023	-

* Estimated data More valuation ratios

Latest news: TRACON Pharmaceuticals, Inc.

24-10-10	TRACON Pharmaceuticals, Inc. announced a financing transaction	CI
24-08-13	TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-07-30	TRACON Pharmaceuticals, Inc. Announces the Appointment of Craig R. Jalbert as President, Treasurer and Secretary, and Sole Member of the Board	CI
24-07-30	TRACON Pharmaceuticals, Inc. Announces the Appointment of Craig R. Jalbert as CEO	CI
24-07-30	TRACON Pharmaceuticals Announces It Will Wind Down Operations	CI
24-07-01	TRACON Pharmaceuticals, Inc.(OTCPK:TCON) dropped from S&P TMI Index	CI
24-07-01	TRACON Pharmaceuticals to Explore Strategic Alternatives Leveraging its In-House Product Development Platform	CI
24-07-01	Tracon to Explore Strategic Alternatives After Trial Misses Target	MT
24-07-01	TRACON Pharmaceuticals Announces Termination of Envasarc Trial and Will Explore Strategic Alternatives Leveraging Its In-House Product Development Platform	CI
24-06-26	TRACON Pharmaceuticals, Inc.(OTCPK:TCON) dropped from NASDAQ Composite Index	CI
24-06-21	TRACON Pharmaceuticals, Inc. Announces Resignation of David Lazar as Chief Business Development Officer	CI
24-06-21	Top Premarket Decliners	MT
24-06-11	TRACON Pharmaceuticals, Inc. Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for Trc102, A Dna Damage Repair Inhibitor, in Recurrent Glioblastoma Patients	CI

More news

Analysts' recommendations: TRACON Pharmaceuticals, Inc.

24-03-06	HC Wainwright Adjusts Price Target on TRACON Pharmaceuticals to $6 From $7, Keeps Buy Rating	MT
23-08-21	JonesTrading Downgrades TRACON Pharmaceuticals to Hold From Buy	MT
23-08-15	Baird Trims Price Target on TRACON Pharmaceuticals to $3 From $7, Maintains Outperform Rating	MT
23-05-11	Maxim Adjusts TRACON Pharmaceuticals' Price Target to $3 From $8, Keeps Buy Rating	MT
23-05-11	Baird Trims Price Target on TRACON Pharmaceuticals to $7 From $8, Maintains Outperform Rating	MT

More recommendations

Press Releases: TRACON Pharmaceuticals, Inc.

24-08-13	Tracon: Q2 Earnings Snapshot	AQ
24-07-30	TRACON Pharmaceuticals Announces it Will Wind Down Operations	AQ
24-07-01	TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform	AQ
24-06-12	TRACON Pharmaceuticals : Failure to Satisfy Listing Rule Form 8 K	PU
24-06-11	TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients	AQ

More press releases

Managers and Directors: TRACON Pharmaceuticals, Inc.

Manager	Title	Age	Since
Craig Jalbert CEO	Chief Executive Officer	65	2024-07-30
James L. Freddo CTO	Chief Tech/Sci/R&D Officer	71	2020-04-30
Brenda Marczi LAW	General Counsel	-	2021-07-19

Director	Title	Age	Since
Craig Jalbert BRD	Director/Board Member	65	2024-07-30

More insiders

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize products in the United States. The Companyâ€™s clinical-stage oncology product candidate is TRC102, which is a small molecule that has been studied in Phase 1 and Phase 2 trials for the treatment of mesothelioma, lung cancer, glioblastoma and solid tumors and YH001, which is a monospecific investigational cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody. TRC102 is a small molecule in clinical development to reverse resistance to specific chemotherapeutics by inhibiting DNA base excision repair (BER). Its clinical-stage product candidate, Envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma.

Employees

Sector

Pharmaceuticals

More about the company

Stock Market
Stocks
TCON Stock

-40%: Exceptional extension

SEIZE THE OFFER!

3 years	0		14.75
5 years	0		89.8
10 years	0		1,460

Date	Insider	Type	Main position	Quantity	% Market Cap.
3/12/24	Charles Theuer	Free	Chief Executive Officer	525,300	1.6867%
3/12/24	Scott Brown	Free	Chief Financial Officer	228,300	0.7330%
11/10/23	Opaleye Management, Inc.	Sell	Company	4,764,008	15.5180%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TRACON PHARMACEUTICALS, INC.	-26.01%	-.--%	-.--%	-99.24%	110K
REGENERON PHARMACEUTICALS, INC.	-0.58%	+0.43%	+32.58%	-5.62%	78.37B
MODERNA, INC.	-2.55%	+6.99%	+510.30%	+48.79%	61.5B
CSL LIMITED	-1.11%	+5.08%	-11.48%	-33.14%	59.78B
SAMSUNG BIOLOGICS CO.,LTD.	+0.14%	-1.20%	-11.21%	+26.46%	46.53B
UCB	-0.24%	+1.22%	+2.36%	+145.46%	45.5B
BIOGEN INC.	-1.62%	-0.76%	+51.23%	-17.28%	31.84B
INCYTE CORPORATION	-1.81%	+3.16%	+44.82%	+107.57%	25.4B
INNOVENT BIOLOGICS, INC.	+0.47%	+3.26%	+4.94%	+151.56%	21.43B
SWEDISH ORPHAN BIOVITRUM AB	+0.27%	+1.96%	+59.19%	+104.48%	15.77B
Average	-3.30%	+2.89%	+68.27%	+42.90%	38.61B
Weighted average by Cap.	-0.92%	+2.35%	+94.90%	+40.16%

	2022	2023
Net sales	-	12.04M 10.5M 9.92M 9.01M 16.87M 1.16B 16.94M 119M 45.84M 588M 45.25M 44.24M 1.89B
Net income	-29.14M -25.41M -23.99M -21.78M -40.81M -2.8B -40.98M -287M -111M -1.42B -109M -107M -4.57B	-3.59M -3.13M -2.95M -2.68M -5.03M -344M -5.05M -35.39M -13.66M -175M -13.48M -13.18M -563M
Net Debt	-6.46M -5.63M -5.32M -4.83M -9.05M -620M -9.09M -63.7M -24.58M -315M -24.26M -23.72M -1.01B	-7.6M -6.62M -6.25M -5.68M -10.64M -729M -10.69M -74.92M -28.91M -371M -28.53M -27.9M -1.19B

TRACON Pharmaceuticals, Inc. Stock

Stocks

TCON

US89237H3084

Pharmaceuticals

Valuation: TRACON Pharmaceuticals, Inc.

Latest news: TRACON Pharmaceuticals, Inc.

Analysts' recommendations: TRACON Pharmaceuticals, Inc.

Press Releases: TRACON Pharmaceuticals, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: TRACON Pharmaceuticals, Inc.

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile